Effect of common methylenetetrahydrofolate reductase gene mutation on coronary artery disease in familial hypercholesterolemia

American Journal of Cardiology

Volumn 86, Issue 8, 2000, Pages 840-845

  Kawashiri, Masa Aki ^a   Kajinami, Kouji ^a   Nohara, Atsushi ^a   Yagi, Kunimasa ^a   Inazu, Akihiro ^a   Koizumi, Junji ^a   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; HOMOCYSTEINE; VALINE;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION FUNCTION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE DOSAGE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; APOLIPOPROTEINS E; CORONARY DISEASE; GENOTYPE; HUMANS; HYPERCHOLESTEROLEMIA, FAMILIAL; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; RESEARCH SUPPORT, NON-U.S. GOV'T;

EID: 0034662779     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01103-6     Document Type: Article

References (29)

1. Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ullmann D., Tishler P.V., Hennekens C.H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 268:1992;877-881.
2. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J., den Heijer M., Kluijtmans L.A., van den Heuvel L.P., Rozen R. A candidate genetic risk factor for vascular disease a common mutation in methylenetetrahydrofolate reductase . Nat Genet. 10:1995;111-113.
3. Kluijtmans L.A., van den Heuvel L.P., Boers G.H., Frosst P., Stevens E.M., van Oost B.A., den Heijer M., Trijbels F.J., Rozen R., Blom H.J. Molecular genetic analysis in mild hyperhomocysteinemia a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease . Am J Hum Genet. 58:1996;35-41.
4. Morita H., Taguchi J., Kurihara H., Kitaoka M., Kaneda H., Kurihara Y., Maemura K., Shindo T., Minamino T., Ohno M., Yamaoki K., Ogasawara K., Aizawa T., Suzuki S., Yazaki Y. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 95:1997;2032-2036.
5. Gallagher P.M., Meleady R., Shields D.C., Tan K.S., McMaster D., Rozen R., Evans A., Graham I.M., Whitehead A.S. Homocysteine and risk of premature coronary heart disease evidence for a common gene mutation . Circulation. 94:1996;2154-2158.
6. Kluijtmans L.A., Kastelein J.J., Lindemans J., Boers G.H., Heil S.G., Bruschke A.V., Jukema J.W., van den Heuvel L.P., Trijbels F.J., Boerma G.J., Verheugt F.W., Willems F., Blom H.J. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 96:1997;2573-2577.
7. Izumi M., Iwai N., Ohmichi N., Nakamura Y., Shimoike H., Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis. 121:1996;293-294.
8. Anderson J.L., King G.J., Thomson M.J., Todd M., Bair T.L., Muhlestein J.B., Carlquist J.F. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 30:1997;1206-1211.
9. Brattström L. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation. 96:1997;3805-3807.
10. Folsom A.R., Nieto F.J., McGovern P.G., Tsai M.Y., Malinow M.R., Eckfeldt J.H., Hess D.L., Davis C.E. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 98:1998;204-210.
11. Brattström L., Wilcken D.E.L., Öhrvik J., Brudin L. Common methylenetetra-hydrofolate redutase gene mutation leads to hyperhomocycteinemia but not to vascular disease the result of a meta-analysis . Circulation. 98:1998;2520-2526.
12. Mabuchi H., Ito S., Haba T., Ueda K., Ueda R. Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by Achilles' tendon thickness. Atherosclerosis. 28:1977;61-68.
13. Mabuchi H., Koizumi J., Shimizu M., Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation. 79:1989;225-232.
14. Committee report. J Jpn Diabetes Soc. 25:1982;859-866.
15. Haraki T., Inazu A., Yagi K., Kajinami K., Koizumi J., Mabuchi H. Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. Atherosclerosis. 132:1997;229-236.
16. Thompson G.R., Seed M., Niththyananthan S., McCarthy S., Thorogood M. Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis. (suppl):1989;I-75-I-80.
17. Ferrieres J., Lambert J., Lussier-Cacan S., Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation. 92:1995;290-295.
18. Vohl M.C., Gaudet D., Moorjani S., Tremblay G., Perron P., Gagne C., Lesiege D., Bergeron J., Lupien P.J., Despres J.P. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolemia. Eur J Clin Invest. 27:1997;366-373.
19. Streja D., Steiner G., Kwiterovich P.O. Jr. Plasma high-density lipoproteins and ischemic heart disease. Ann Intern Med. 89:1978;871-880.
20. Hirobe K., Matsuzawa Y., Ishikawa K., Tarui S., Yamamoto A., Nambu S., Fujimoto K. Coronary artery disease in heterozygous familial hypercholesterolemia. Atherosclerosis. 44:1982;201-210.
21. Lindahl G., Mailly F., Humphries S., Seed M. Apolipoprotein E phenotype and lipoprotein(a) in familial hypercholesterolemia implication for lipoprotein(a) metabolism . Clin Invest. 72:1994;631-638.
22. Yanagi K., Yamashita S., Kihara S., Nakamura T., Nozaki S., Nagai Y., Funahashi T., Kameda-Takemura K., Ueyama Y., Jiao S., Kubo M., Tokunaga K., Matsuzawa Y. Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance. Atherosclerosis. 132:1997;43-51.
23. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia an independent risk factor for vascular disease . N Engl J Med. 324:1991;1149-1155.
24. Genest J.J. Jr, McNamara J.R., Upson B., Salem D.N., Ordovas J.M., Schaefer E.J., Malinow M.R. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb. 11:1991;1129-1136.
25. Nygard O., Vollset S.E., Refsum H., Stensvold I., Tverdal A., Nordrehaug J.E., Ueland M., Kvale G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 274:1995;1526-1533.
26. Tonstad S., Refsum H., Ueland P.M. Association between plasma total homocysteine and parental history of cardiovascular disease in children with familial hypercholesterolemia. Circulation. 96:1997;1803-1808.
27. Vuorio A.F., Turtola H., Piilahti K.M., Repo P., Kanninen T., Kontula K. Familial hypercholesterolemia in Finnish north Karelia. Arterioscler Thromb Vasc Biol. 17:1997;3127-3138.
28. Eto M., Watanabe K., Chonan N., Ishii K. Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis. 72:1988;123-128.
29. Malinow M.R., Nieto F.J., Kruger W.D., Duell P.B., Hess D.L., Gluckman R.A., Block P.C., Holzgang C.R., Anderson P.H., Seltzer D., Upson B., Lin Q.R. The effect of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol. 17:1997;1157-1162.